Cargando…

A glucagon-like peptide-1 analog, liraglutide, ameliorates endothelial dysfunction through miRNAs to inhibit apoptosis in rats

BACKGROUND AND AIMS: Many studies have revealed that glucagon-like peptide-1 has vasoprotective effects. In this study, we investigated whether liraglutide suppressed endothelial dysfunction and explored the mechanism involved. METHODS: Experimental diabetes was induced through combined high-fat die...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Qian, Xiao, Xinhua, Zheng, Jia, Li, Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PeerJ Inc. 2019
Materias:	Diabetes and Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408912/ https://www.ncbi.nlm.nih.gov/pubmed/30863684 http://dx.doi.org/10.7717/peerj.6567

Ejemplares similares

Glucagon Like Peptide 1 and MicroRNA in Metabolic Diseases: Focusing on GLP1 Action on miRNAs
por: Capuani, Barbara, et al.
Publicado: (2018)

Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study
por: Dejgaard, Thomas Fremming, et al.
Publicado: (2015)

Weight Loss Effects of Glucagon-Like Peptide-One Receptor Analog Treatment in a Severely Obese Patient During Hospital Admission
por: Figueredo, Yaiseli, et al.
Publicado: (2023)

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
por: Sawada, Noritaka, et al.
Publicado: (2020)

Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea–hypnoea index (AHI)
por: Sprung, Victoria S, et al.
Publicado: (2020)

Glucagon-Like Peptide-1 Analog, Liraglutide, Delays Onset of Experimental Autoimmune Encephalitis in Lewis Rats
por: DellaValle, Brian, et al.
Publicado: (2016)

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
por: Robinson, Louise E, et al.
Publicado: (2013)

Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism
por: Krasner, Nadia M., et al.
Publicado: (2014)

The Impact of Glucagon-Like Peptide-1 on Bone Metabolism and Its Possible Mechanisms
por: Zhao, Chenhe, et al.
Publicado: (2017)

Glucagon-like peptide-1 analog liraglutide leads to multiple metabolic alterations in diet-induced obese mice
por: Park, Seokjae, et al.
Publicado: (2022)

Liraglutide-Induced Pancreatitis: A Case Report and Literature Review
por: Javed, Hamna, et al.
Publicado: (2023)

The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial
por: Foghsgaard, Signe, et al.
Publicado: (2013)

Effectiveness, Safety, and Patient Satisfaction of Liraglutide in Type 2 Diabetic Patients
por: Zameer, Rafia, et al.
Publicado: (2020)

Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article
por: Ghazanfar, Haider, et al.
Publicado: (2021)

Glucagon-Like Peptide-1 Analog Liraglutide Protects against Diabetic Cardiomyopathy by the Inhibition of the Endoplasmic Reticulum Stress Pathway
por: Liu, Jieyu, et al.
Publicado: (2013)

Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
por: Berman, Casey, et al.
Publicado: (2023)

Role of Glucagon-Like Peptide-1 Receptor Agonists on the Weight Loss of Individuals With Type 2 Diabetes: A Systematic Review
por: Irfan, Huma, et al.
Publicado: (2023)

Suspected Gastroparesis With Concurrent Gastroesophageal Reflux Disease Induced by Low-Dose Liraglutide
por: Ishihara, Yo, et al.
Publicado: (2022)

Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol
por: Hussein, Humaira, et al.
Publicado: (2018)

Identification of altered miRNAs and their targets in placenta accreta
por: Murrieta-Coxca, José M., et al.
Publicado: (2023)

What Is Best for Weight Loss? A Comparative Review of the Safety and Efficacy of Bariatric Surgery Versus Glucagon-Like Peptide-1 Analogue
por: Klair, Nimra, et al.
Publicado: (2023)

Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet
por: Jensen, Simon Birk Kjær, et al.
Publicado: (2019)

GH and IGF System: The Regulatory Role of miRNAs and lncRNAs in Cancer
por: Catellani, Cecilia, et al.
Publicado: (2021)

Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial
por: Papamargaritis, Dimitris, et al.
Publicado: (2020)

Weight Loss of Over 100 lbs in a Patient of Prader-Willi Syndrome Treated With Glucagon-Like Peptide-1 (GLP-1) Agonists
por: Ahmed, Sana, et al.
Publicado: (2023)

Hypothalamic miRNAs: emerging roles in energy balance control
por: Schneeberger, Marc, et al.
Publicado: (2015)

Identification of biomarkers and prediction of upstream miRNAs in diabetic nephropathy
por: Yin, Dapeng, et al.
Publicado: (2023)

Multifocal C-cell Hyperplasia and Marked Hypercalcitoninemia in a Diabetic Patient Treated With Glucagon-Like Peptide-1 Agonist With Concurrent Multinodular Goiter and Hyperparathyroidism
por: Zou, Sifan, et al.
Publicado: (2023)

The Glucagon-Like Peptide-1 Analogue Liraglutide Reduces Seizures Susceptibility, Cognition Dysfunction and Neuronal Apoptosis in a Mouse Model of Dravet Syndrome
por: Liu, Shenhai, et al.
Publicado: (2020)

Impact of glucagon-like peptide 1 analogs on cognitive function among patients with type 2 diabetes mellitus: A systematic review and meta−analysis
por: Luan, Sisi, et al.
Publicado: (2022)

Emerging Evidence for the Use of Antidiabetic Drugs, Glucagon-like Peptide 1 Receptor Agonists, for the Treatment of Alzheimer’s Disease
por: Colin, Ides M, et al.
Publicado: (2023)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiovascular Risk Management in Patients With Type 2 Diabetes Mellitus: A Systematic Review
por: Parab, Panah, et al.
Publicado: (2023)

Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
por: Paternoster, Silvano, et al.
Publicado: (2018)

Chronic Administration of the Glucagon-Like Peptide-1 Analog, Liraglutide, Delays the Onset of Diabetes and Lowers Triglycerides in UCD-T2DM Rats
por: Cummings, Bethany P., et al.
Publicado: (2010)

Metformin ameliorates insulitis in STZ-induced diabetic mice
por: Han, Xue, et al.
Publicado: (2017)

Safety and Efficacy of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
por: Vemulapalli, Hema Srikanth, et al.
Publicado: (2023)

Successful Resolution of Glucose Toxicity With the Use of Fixed-Ratio Combination Injection of Basal Insulin and Short-Acting Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist
por: Miura, Hiroshi, et al.
Publicado: (2022)

Corrigendum: Hypothalamic miRNAs: emerging roles in energy balance control
por: Schneeberger, Marc, et al.
Publicado: (2015)

miRNAs as Predictive Factors in Early Diagnosis of Gestational Diabetes Mellitus
por: Juchnicka, Ilona, et al.
Publicado: (2022)

Characteristics of miRNAs Present in Bovine Sperm and Associations With Differences in Fertility
por: Werry, Nicholas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dp3em0s48bl8dnsk0qtt7ibajc